Key result
BNP testing guides HF diagnosis, prognosis, and therapeutic monitoring with potential applications in cardiac rehabilitation.
Why the study?
There is a need to summarize the evidence for diagnostic, prognostic, and therapeutic uses of BNP and explore its applications in cardiac rehabilitation.
This review highlights the established role of BNP and NT-proBNP testing in heart failure management and explores its potential utility in cardiac rehabilitation.
Affirms BNP utility in heart failure; leaves open its role in cardiac rehabilitation pending prospective data.
Biomarker assays for B-type natriuretic peptide (BNP) and its precursor N-terminal pro-BNP(NT-proBNP) are recommended in heart failure clinical practice. Cowie et al (2010) have recently reported that there is firm evidence for natriuretic peptide (NP) testing as part of the heart failure diagnostic pathway and as a prognostic tool, and the recent 2010 update to the National Institute for Health and Clinical Excellence guidelines on heart failure refers to the use of NP testing to aid diagnosis and identify patients requiring further treatment. In addition, there is growing evidence for use in monitoring treatment. This article summarizes the existing well-reported evidence for the diagnostic, prognostic and therapeutic uses of BNP. In addition, it discusses possible applications in a cardiac rehabilitation setting.
No takes yet. Share an insight, caveat, or question.
Rosalind Leslie (2010) conducted a review in Heart failure. B-type natriuretic peptide (BNP) testing was evaluated. B-type natriuretic peptide (BNP) testing has established evidence for diagnostic, prognostic, and therapeutic monitoring in heart failure, with potential applications in cardiac rehabilitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: